International Journal of Clinical Research
International Journal of Clinical Research. 2025; 9: (3) ; 10.12208/j.ijcr.20250120 .
总浏览量: 97
1 曲阜市人民医院 山东曲阜
2 兰陵县人民医院皮肤科 山东临沂
*通讯作者： 张雨晴,单位： 曲阜市人民医院 山东曲阜；
白癜风作为一种常见的色素脱失性皮肤病，其发病机制复杂，且常与多种其他疾病相伴发生。本文旨在深入探讨白癜风的共病情况，涵盖自身免疫性疾病、内分泌疾病、代谢紊乱、神经系统异常以及精神心理障碍等多个领域。通过综合分析共病的发病机制、流行病学特征以及临床管理要点，为白癜风患者的综合治疗提供科学依据，以提升患者的整体健康水平和生活质量。
Vitiligo, as a common pigment-loss skin disease, has a complex pathogenesis and is often accompanied by a variety of other diseases. This article aims to deeply explore the comorbidities of vitiligo, covering multiple fields such as autoimmune diseases, endocrine diseases, metabolic disorders, neurological abnormalities and psychiatric and psychological disorders. Through a comprehensive analysis of the pathogenesis, epidemiological characteristics and key points of clinical management of comorbidities, it provides a scientific basis for the comprehensive treatment of vitiligo patients, so as to improve the overall health level and quality of life of patients.
[1] Lee JH, Ju HJ, Seo JM, et al. Comorbidities in Patients with Vitiligo[J]. J Invest Dermatol. 2023;143(5):777-789.e6.
[2] Lim HK, Bae MI, Jeong KH, et al. Positivity rates of antithyroid antibody, antinuclear antibody and thyroid peroxidase antibody in different types of vitiligo[J]. Clin Exp Dermatol. 2016;41(3):242-247.
[3] Yuan J, Sun C, Jiang S, et al. The Prevalence of Thyroid Disorders in Patients With Vitiligo[J]. Front Endocrinol (Lausanne). 2018;9:803.
[4] Fan KC, Yang TH, and Huang YC. Vitiligo and thyroid disease[J]. Eur J Dermatol. 2018;28(6):750-763.
[5] Tang Q, Sousa J, Echeverria D, et al. RNAi-based modulation of IFN-γ signaling in skin[J]. Mol Ther. 2022;30(8):2709-2721.
[6] Maouia A, Sormani L, Youssef M, et al. Differential expression of CXCL9, CXCL10, and IFN-γ in vitiligo and alopecia areata patients[J]. Pigment Cell Melanoma Res. 2017;30(2):259-261.
[7] Spritz RA, and Santorico SA. The Genetic Basis of Vitiligo[J]. J Invest Dermatol. 2021;141(2):265-273.
[8] Barbulescu CC, Goldstein NB, Roop DR, et al. Harnessing the Power of Regenerative Therapy for Vitiligo and Alopecia Areata[J]. J Invest Dermatol. 2020;140(1):29-37.
[9] Moya EC, Bruinsma RL, Kelly KA, et al. How suitable are JAK inhibitors in treating the inflammatory component in patients with alopecia areata and vitiligo?[J]. Expert Rev Clin Immunol. 2022;18(3):189-191.
[10] Hu S, Che Y, Cai J, et al. Diabetes, glycemic profile and risk of vitiligo[J]. Skin Res Technol. 2024;30(7):e13787.
[11] Márquez A, and Martín J. Genetic overlap between type 1 diabetes and other autoimmune diseases[J]. Semin Immunopathol. 2022;44(1):81-97.
[12] Hadi A, Wang JF, Uppal P, et al. Comorbid diseases of vitiligo[J]. J Am Acad Dermatol. 2020;82(3):628-633.
[13] Zhao M, Zhang Y, and Sun G. Identifying the genetic association between common rheumatic diseases and vitiligo[J]. Skin Res Technol. 2024;30(7):e13846.
[14] Fichna M, Małecki PP, Młodzikowska M, et al. Increased risk of endocrine autoimmunity in first-degree relatives of patients with autoimmune Addison’s disease[J]. Eur J Endocrinol. 2020;183(1):73-81.
[15] Fichna M, Żurawek M, Słomiński B, et al. Polymorphism in BACH2 gene is a marker of polyglandular autoimmunity[J]. Endocrine. 2021;74(1):72-79.
[16] Zwick D, Vo MT, Shim YJ, et al. BACH2[J]. Cells. 2024; 13(11):891.
[17] Chuang KW, and Chang HC. Association between vitiligo and metabolic syndrome[J]. J Dtsch Dermatol Ges. 2022;20(2): 218-221.
[18] Kridin K, Lyakhovitsky K, Barhoum M, et al. Vitiligo and the metabolic syndrome[J]. Arch Dermatol Res. 2024;316(7):408.
[19] Namazi N, Amani M, Haghighatkhah HR, et al. Increased risk of subclinical atherosclerosis and metabolic syndrome in patients with vitiligo[J]. Dermatol Ther. 2021;34(2):e14803.
[20] Genedy R, Assal S, Gomaa A, et al. Ocular and auditory abnormalities in patients with vitiligo[J]. Clin Exp Dermatol. 2021;46(6):1058-1066.
[21] Ezzedine K, Soliman AM, Li C, et al. Comorbidity Burden Among Patients with Vitiligo in the United States[J]. Dermatol Ther (Heidelb). 2023;13(10):2265-2277.
[22] Ma SH, Ang MD, Chang YT, et al. Association between vitiligo and hearing loss[J]. J Am Acad Dermatol. 2021; 85(6):1465-1472.
[23] Lien KH, Ger TY, and Chi CC. Association of vitiligo with high-frequency sensorineural hearing loss[J]. J Eur Acad Dermatol Venereol. 2022;36(3):373-379.
[24] Baizabal-Carvallo JF, and Alonso-Juarez M. Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies[J]. J Neural Transm (Vienna). 2017;124(10):1171-1182.
[25] Bai L, Ren H, Liang M, et al. Neurological disorders associated with glutamic acid decarboxylase 65 antibodies[J]. Front Neurol. 2022;13:990553.
[26] Wang Y, Yao T, Lin Y, et al. Exploring genetic associations between vitiligo and mental disorders using Mendelian randomization[J]. Exp Dermatol. 2024;33(1):e14979.
[27] Seneschal J. Clinical Features of Vitiligo and Social Impact on Quality of Life[J]. Dermatol Pract Concept. 2023;13(4S2): e2023312S.
[28] Simons RE, Zevy DL, and Jafferany M. Psychodermatology of vitiligo[J]. Dermatol Ther. 2020;33(3):e13418.
[29] Ramot Y, Rosenberg V, Zhou L, et al. Epidemiology and Treatment Patterns of Patients with Vitiligo[J]. Adv Ther. 2024;41(7):2890-2906.
[30] Kussainova A, Kassym L, Akhmetova A, et al. Vitiligo and anxiety[J]. PLoS One. 2020;15(11):e0241445.